Cancer Precision Medicine in China

Genomics, Proteomics and Bioinformatics

Volumn 14, Issue 5, 2016, Pages 325-328

  Li, Hui ^a,b  

^a KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BIOLOGICAL MARKER; LONG UNTRANSLATED RNA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MICRORNA; TELOMERASE REVERSE TRANSCRIPTASE;

CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RESEARCH; CANCER TISSUE; CHINA; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DIGESTIVE SYSTEM CANCER; GENETIC SCREENING; GENOMICS; GLIOBLASTOMA; HUMAN; MICROSATELLITE INSTABILITY; MULTIPLE CANCER; NEXT GENERATION SEQUENCING; NONHUMAN; NOTE; PERSONALIZED MEDICINE; PHARYNX CANCER; STOMACH CANCER;

EID: 84994509044     PISSN: 16720229     EISSN: 22103244     Source Type: Journal    
DOI: 10.1016/j.gpb.2016.10.002     Document Type: Note

References (12)

1. [1] Song, Y., Li, L., Ou, Y., Gao, Z., Li, E., Li, X., et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509 (2014), 91–95.
2. [2] Sawasdikosol, S., Zha, R., Yang, B., Burakoff, S., HPK1 as a novel target for cancer immunotherapy. Immunol Res 54 (2012), 262–265.
3. [3] Brentjens, R.J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 13 (2007), 5426–5435.
4. [4] Brentjens, R.J., Davila, M.L., Riviere, I., Park, J., Wang, X., Cowell, L.G., et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med, 5, 2013, 177ra38.
5. [5] Chekmasova, A.A., Rao, T.D., Nikhamin, Y., Park, K.J., Levine, D.A., Spriggs, D.R., et al. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res 16 (2010), 3594–3606.
6. [6] Lee, J.C., Hayman, E., Pegram, H.J., Santos, E., Heller, G., Sadelain, M., et al. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res 71 (2011), 2871–2881.
7. [7] Pegram, H.J., Lee, J.C., Hayman, E.G., Imperato, G.H., Tedder, T.F., Sadelain, M., et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119 (2012), 4133–4141.
8. [8] Stephan, M.T., Ponomarev, V., Brentjens, R.J., Chang, A.H., Dobrenkov, K.V., Heller, G., et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 13 (2007), 1440–1449.
9. [9] Dai, H., Zhang, W., Li, X., Han, Q., Guo, Y., Zhang, Y., et al. Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology, 4, 2015, e1027469.
10. [10] Wang, Y., Zhang, W.Y., Han, Q.W., Liu, Y., Dai, H.R., Guo, Y.L., et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. Clin Immunol 155 (2014), 160–175.
11. [11] Feng, K., Guo, Y., Dai, H., Wang, Y., Li, X., Jia, H., et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci 59 (2016), 468–479.
12. [12] Lin, J.J., Cardarella, S., Lydon, C.A., Dahlberg, S.E., Jackman, D.M., Jänne, P.A., et al. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol 11 (2016), 556–565.